- Home
- ACVA vs CRSP Comparison
ACVA vs CRSP Comparison
Compare ACVA & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACVA
- CRSP
- Stock Information
- Founded
- ACVA 2014
- CRSP 2013
- Country
- ACVA United States
- CRSP Switzerland
- Employees
- ACVA N/A
- CRSP N/A
- Industry
- ACVA Business Services
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACVA Consumer Discretionary
- CRSP Health Care
- Exchange
- ACVA Nasdaq
- CRSP Nasdaq
- Market Cap
- ACVA 3.4B
- CRSP 3.4B
- IPO Year
- ACVA 2021
- CRSP 2016
- Fundamental
- Price
- ACVA $21.53
- CRSP $40.53
- Analyst Decision
- ACVA Strong Buy
- CRSP Buy
- Analyst Count
- ACVA 9
- CRSP 19
- Target Price
- ACVA $24.22
- CRSP $77.13
- AVG Volume (30 Days)
- ACVA 1.3M
- CRSP 1.8M
- Earning Date
- ACVA 02-19-2025
- CRSP 02-19-2025
- Dividend Yield
- ACVA N/A
- CRSP N/A
- EPS Growth
- ACVA N/A
- CRSP N/A
- EPS
- ACVA N/A
- CRSP N/A
- Revenue
- ACVA $596,019,000.00
- CRSP $202,829,000.00
- Revenue This Year
- ACVA $34.25
- CRSP N/A
- Revenue Next Year
- ACVA $24.47
- CRSP $724.16
- P/E Ratio
- ACVA N/A
- CRSP N/A
- Revenue Growth
- ACVA 29.34
- CRSP 19.31
- 52 Week Low
- ACVA $12.84
- CRSP $36.52
- 52 Week High
- ACVA $23.46
- CRSP $91.10
- Technical
- Relative Strength Index (RSI)
- ACVA 53.30
- CRSP 44.09
- Support Level
- ACVA $19.93
- CRSP $36.52
- Resistance Level
- ACVA $22.00
- CRSP $40.99
- Average True Range (ATR)
- ACVA 0.83
- CRSP 1.78
- MACD
- ACVA 0.01
- CRSP 0.23
- Stochastic Oscillator
- ACVA 71.43
- CRSP 51.68
About ACVA ACV Auctions Inc.
ACV Auctions Inc is a mobile platform for wholesale car auctions. It provides a digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information for customers.
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.